KR101581961B1 - Ａｌｋ１ 수용체 및 리간드 길항제 및 그의 용도 - Google Patents

Ａｌｋ１ 수용체 및 리간드 길항제 및 그의 용도 Download PDF

Info

Publication number
KR101581961B1
KR101581961B1 KR1020097011291A KR20097011291A KR101581961B1 KR 101581961 B1 KR101581961 B1 KR 101581961B1 KR 1020097011291 A KR1020097011291 A KR 1020097011291A KR 20097011291 A KR20097011291 A KR 20097011291A KR 101581961 B1 KR101581961 B1 KR 101581961B1
Authority
KR
South Korea
Prior art keywords
delete delete
alk1
angiogenesis
leu
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020097011291A
Other languages
English (en)
Korean (ko)
Other versions
KR20090085662A (ko
Inventor
아샤 그린베르그
존 노프
래빈드라 쿠마
로버트 스콧 피어샐
제이스버 시라
Original Assignee
악셀레론 파마 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 악셀레론 파마 인코포레이티드 filed Critical 악셀레론 파마 인코포레이티드
Publication of KR20090085662A publication Critical patent/KR20090085662A/ko
Application granted granted Critical
Publication of KR101581961B1 publication Critical patent/KR101581961B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
KR1020097011291A 2006-11-02 2007-11-02 Ａｌｋ１ 수용체 및 리간드 길항제 및 그의 용도 Expired - Fee Related KR101581961B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85659206P 2006-11-02 2006-11-02
US60/856,592 2006-11-02

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020147033523A Division KR20150008889A (ko) 2006-11-02 2007-11-02 Ａｌｋ１ 수용체 및 리간드 길항제 및 그의 용도

Publications (2)

Publication Number Publication Date
KR20090085662A KR20090085662A (ko) 2009-08-07
KR101581961B1 true KR101581961B1 (ko) 2016-01-04

Family

ID=39365087

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020097011291A Expired - Fee Related KR101581961B1 (ko) 2006-11-02 2007-11-02 Ａｌｋ１ 수용체 및 리간드 길항제 및 그의 용도
KR1020147033523A Withdrawn KR20150008889A (ko) 2006-11-02 2007-11-02 Ａｌｋ１ 수용체 및 리간드 길항제 및 그의 용도
KR1020177001896A Ceased KR20170012582A (ko) 2006-11-02 2007-11-02 Ａｌｋ１ 수용체 및 리간드 길항제 및 그의 용도

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020147033523A Withdrawn KR20150008889A (ko) 2006-11-02 2007-11-02 Ａｌｋ１ 수용체 및 리간드 길항제 및 그의 용도
KR1020177001896A Ceased KR20170012582A (ko) 2006-11-02 2007-11-02 Ａｌｋ１ 수용체 및 리간드 길항제 및 그의 용도

Country Status (14)

Country Link
US (4) US8455428B2 (enExample)
EP (2) EP2087001B1 (enExample)
JP (5) JP2010508816A (enExample)
KR (3) KR101581961B1 (enExample)
CN (2) CN111518218A (enExample)
AU (1) AU2007317926A1 (enExample)
BR (1) BRPI0717964A2 (enExample)
CA (1) CA2668411C (enExample)
DK (1) DK2087001T3 (enExample)
ES (1) ES2612755T3 (enExample)
IL (2) IL198522A (enExample)
MX (1) MX2009004718A (enExample)
RU (2) RU2559532C2 (enExample)
WO (1) WO2008057461A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8764725B2 (en) 2004-02-09 2014-07-01 Covidien Lp Directional anchoring mechanism, method and applications thereof
WO2006091930A2 (en) * 2005-02-24 2006-08-31 Massachusetts Eye & Ear Infirmary Methods and compounds for promoting vessel regression
US10059756B2 (en) 2006-11-02 2018-08-28 Acceleron Pharma Inc. Compositions comprising ALK1-ECD protein
US8642031B2 (en) 2006-11-02 2014-02-04 Acceleron Pharma, Inc. Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
BRPI0717964A2 (pt) * 2006-11-02 2013-12-17 Acceleron Pharma Inc Receptor e antagonistas de ligante da alk1 e usos dos mesmos.
CN101918022A (zh) * 2007-11-09 2010-12-15 健泰科生物技术公司 激活蛋白受体样激酶-1组合物及使用方法
US7855564B2 (en) * 2008-02-14 2010-12-21 Delaware Capital Formation, Inc. Acoustic wave device physical parameter sensor
EP3398966A1 (en) * 2008-05-02 2018-11-07 Acceleron Pharma, Inc. Methods and compositions for modulating angiogenesis and pericyte composition
EP2291401A2 (en) * 2008-05-15 2011-03-09 Acceleron Pharma, Inc. Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof
WO2010126169A1 (ja) * 2009-04-30 2010-11-04 協和発酵キリン株式会社 Alk1阻害剤を有効成分とする血管障害を抑制するための医薬組成物
WO2011056494A1 (en) * 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
US9932386B2 (en) 2011-04-20 2018-04-03 Acceleron Pharma, Inc. Endoglin polypeptides and uses thereof
KR101421171B1 (ko) * 2011-08-31 2014-07-22 재단법인 제이씨비 공동생물과학연구소 인간 골형성 단백질 수용체 1ａ의 세포외 도메인을 유효성분으로 포함하는 피부 상태 개선용 조성물
RU2633638C2 (ru) * 2012-02-02 2017-10-16 Акселерон Фарма Инк. Антагонисты alk1 и их применение в лечении почечно-клеточной карциномы
CA2928708A1 (en) 2013-10-25 2015-04-30 Acceleron Pharma, Inc. Endoglin peptides to treat fibrotic diseases
EP3122381A4 (en) * 2014-03-28 2017-11-08 Acceleron Pharma, Inc. Use of activin receptor-like kinase 1 (alk-1) antagonists in the treatment of cancer
GB201412290D0 (en) 2014-07-10 2014-08-27 Cambridge Entpr Ltd Novel use
JP2016036322A (ja) * 2014-08-11 2016-03-22 日本化薬株式会社 血管新生因子と結合するキメラタンパク質
AU2016246602B2 (en) 2015-04-06 2020-11-19 Acceleron Pharma Inc. Single-arm type I and type II receptor fusion proteins and uses thereof
MA41916A (fr) * 2015-04-06 2021-04-14 Acceleron Pharma Inc Hétéromultimères de récepteur de type i et de type ii de la superfamille de tgf-bêta et leurs utilisations
EA201792561A1 (ru) 2015-06-05 2018-04-30 Новартис Аг Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения
CN105254764A (zh) * 2015-08-27 2016-01-20 上海康岱生物医药技术有限公司 ACVR1-Fc融合蛋白及其制法和用途
US20210403549A1 (en) * 2017-05-17 2021-12-30 Yale University Compounds and compositions that inhibit or prevent lipoprotein entry into the endothelium
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8529014D0 (en) 1985-11-25 1986-01-02 Biogen Nv Enhanced secretion of heterologous proteins
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5350836A (en) 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
CA2104964A1 (en) 1991-02-28 1992-08-29 Ruth Sager Cancer diagnosis and therapy with tumor suppressor genes
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
US5288931A (en) 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5830847A (en) 1992-10-30 1998-11-03 Hsc Research & Development Limited Partnership Soluble TGF-β-binding endoglin polypeptides and homodimers
CA2147754A1 (en) 1992-10-30 1994-05-11 Michelle Letarte Compositions and methods for modifying the regulatory activity of tgf- .beta.
US6692925B1 (en) 1992-11-17 2004-02-17 Ludwig Institute For Cancer Research Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use
US7592428B1 (en) 1992-11-17 2009-09-22 Ludwig Institute For Cancer Research Antibodies which bind specifically to activin receptor like kinases
ATE234920T1 (de) 1992-11-17 2003-04-15 Ludwig Inst Cancer Res Aktivin-rezeptor-ähnliche kinasen, proteine mit serin/threonin kinase domänen und deren anwendungen
EP1439190A1 (en) 1993-01-12 2004-07-21 The Johns Hopkins University School Of Medicine Growth differentiation factor-5
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
CA2229557A1 (en) 1995-08-14 1997-02-27 Creative Biomolecules, Inc. Binding of osteogenic protein-i (op-1) and analogs thereof to the cell surface receptor alk-1 and analogs thereof
ATE214075T1 (de) 1996-05-31 2002-03-15 Health Research Inc Monoklonale antikörper gegen endoglin und ihre verwendung in der anti-angiogenese-therapie
US6190660B1 (en) 1996-05-31 2001-02-20 Health Research, Inc. Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy
MX9701946A (es) 1997-03-14 1998-04-30 Arturo Jimenez Bayardo Solucion oftalmica transportadora.
WO1998047531A2 (en) 1997-04-21 1998-10-29 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy
JP2001510042A (ja) 1997-07-15 2001-07-31 イミュネックス・コーポレーション Ｔｒａｉｌ受容体
EP2078752A3 (en) 1998-03-13 2009-09-23 Ludwig Institute For Cancer Research ALK-1 responds to TGF-beta and signals through SMAD-1 and SMAD-5
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
US6413513B1 (en) 1998-05-22 2002-07-02 Entremed, Inc. Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers
US20030012792A1 (en) 1998-05-22 2003-01-16 Holaday John W. Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers
GB9912350D0 (en) 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
CA2376018A1 (en) * 1999-06-03 2000-12-14 Human Genome Sciences, Inc. Angiogenic proteins and uses thereof
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
PT1255752E (pt) 2000-02-15 2007-10-17 Pharmacia & Upjohn Co Llc Inibidores de proteína quinases: 2-indolinonas substituídas com pirrolo
US7077836B2 (en) 2000-07-21 2006-07-18 Vein Rx, Inc. Methods and apparatus for sclerosing the wall of a varicose vein
AU2001283108A1 (en) 2000-08-03 2002-02-18 The University Of Utah Research Foundation Manipulation of arterial-venous identity
DE10043481A1 (de) 2000-09-04 2002-04-11 Vectron Therapeutics Ag Imt Humaner Antikörper gegen Endoglin (CD105) und seine Verwendung
DK1343782T3 (da) 2000-12-21 2009-08-24 Smithkline Beecham Corp Pyrimidinaminer som angiogenesemodulatorer
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
FI117667B (fi) 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
RU2336902C2 (ru) 2001-10-31 2008-10-27 Алькон, Инк. Морфогенные белки кости (вмр), рецепторы вмр и связывающие вмр белки и их применение для диагностики и лечения глаукомы
WO2003064383A2 (en) 2002-02-01 2003-08-07 Ariad Gene Therapeutics, Inc. Phosphorus-containing compounds & uses thereof
WO2003064628A2 (en) 2002-02-01 2003-08-07 Curagen Corporation Novel proteins and nucleic acids encoding same
US7045534B2 (en) * 2002-02-12 2006-05-16 The Board Of Trustees Of The Leland Stanford Junior University Methods of reducing angiogenesis
EP1534737A4 (en) 2002-04-29 2007-10-31 Univ Saint Louis PEPTIDANTAGONISTS OF MEMBERS OF THE TGF BETA FAMILY AND THEIR THERAPEUTIC APPLICATION
CA2490713A1 (en) 2002-06-27 2004-01-08 University Of Utah Research Foundation Methods and compositions for manipulating the guided navigation of endothelial tubes during angiogenesis
WO2004039248A2 (en) 2002-10-31 2004-05-13 The General Hospital Corporation Repairing or replacing tissues or organs
WO2005010049A2 (en) 2003-07-09 2005-02-03 Eli Lilly And Company Tgf-beta1 ligands
WO2005044849A2 (en) 2003-08-05 2005-05-19 Eli Lilly And Company Lp mammalian proteins; related reagents
EP1697520A2 (en) 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
AU2005248530A1 (en) 2004-01-27 2005-12-08 Compugen Ltd. Differential expression of markers in ovarian cancer
EP1740609A2 (en) 2004-04-27 2007-01-10 Research Development Foundation Antagonism of tgf-beta superfamily receptor signaling
WO2005113590A2 (en) * 2004-05-12 2005-12-01 Acceleron Pharma Inc. Bmp10 propeptides and related methods
EP2314617B1 (en) * 2004-07-23 2015-06-24 Acceleron Pharma Inc. ActRII receptor polypeptides
WO2006091930A2 (en) 2005-02-24 2006-08-31 Massachusetts Eye & Ear Infirmary Methods and compounds for promoting vessel regression
AU2006223301B2 (en) * 2005-03-10 2010-11-04 Eisai, Inc. Anti-mesothelin antibodies
CN101517068B (zh) * 2005-09-07 2017-02-08 安进弗里蒙特公司 活化素受体样激酶‑1的人单克隆抗体
WO2007124143A2 (en) 2006-04-21 2007-11-01 Wyeth Methods for high-throughput screening of cell lines
WO2007143023A1 (en) 2006-05-31 2007-12-13 Beth Israel Deaconess Medical Center Soluble endoglin compounds and uses thereof for the treatment and prevention of cancer
BRPI0717964A2 (pt) * 2006-11-02 2013-12-17 Acceleron Pharma Inc Receptor e antagonistas de ligante da alk1 e usos dos mesmos.
US8642031B2 (en) 2006-11-02 2014-02-04 Acceleron Pharma, Inc. Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
US10059756B2 (en) 2006-11-02 2018-08-28 Acceleron Pharma Inc. Compositions comprising ALK1-ECD protein
CN101918022A (zh) 2007-11-09 2010-12-15 健泰科生物技术公司 激活蛋白受体样激酶-1组合物及使用方法
EP3398966A1 (en) 2008-05-02 2018-11-07 Acceleron Pharma, Inc. Methods and compositions for modulating angiogenesis and pericyte composition
EP2291401A2 (en) 2008-05-15 2011-03-09 Acceleron Pharma, Inc. Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof
EP2364371A4 (en) 2008-11-24 2012-05-02 Univ Loma Linda BIOMARKER FOR DETECTING HEADS AND HALSTUMORS
US20120183543A1 (en) 2009-05-08 2012-07-19 Novartis Ag Diagnostic biomarkers for fibrotic disorders
AU2012212047A1 (en) 2011-02-03 2013-08-22 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
RU2633638C2 (ru) 2012-02-02 2017-10-16 Акселерон Фарма Инк. Антагонисты alk1 и их применение в лечении почечно-клеточной карциномы
US20140193425A1 (en) 2012-10-05 2014-07-10 Acceleron Pharma, Inc. Treatment of cancer with alk1 antagonists
EP3122381A4 (en) 2014-03-28 2017-11-08 Acceleron Pharma, Inc. Use of activin receptor-like kinase 1 (alk-1) antagonists in the treatment of cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Chest. 128(6 Suppl): 585S-590S(2005. 12.)*
Int. J. Clin. Pract. 59(1): 114-118(2005. 1.)*
J. Biol. Chem. 280(26): 25111-25118(2005. 4. 25.)*

Also Published As

Publication number Publication date
WO2008057461A2 (en) 2008-05-15
BRPI0717964A2 (pt) 2013-12-17
IL198522A (en) 2017-06-29
US20220296708A1 (en) 2022-09-22
US20080175844A1 (en) 2008-07-24
US8455428B2 (en) 2013-06-04
RU2559532C2 (ru) 2015-08-10
DK2087001T3 (en) 2017-02-06
IL253035A0 (en) 2017-08-31
EP3181580A1 (en) 2017-06-21
JP2010508816A (ja) 2010-03-25
EP2087001B1 (en) 2016-10-26
JP6348448B2 (ja) 2018-06-27
KR20150008889A (ko) 2015-01-23
RU2009120695A (ru) 2010-12-10
CN101652387A (zh) 2010-02-17
JP2015143269A (ja) 2015-08-06
WO2008057461A3 (en) 2009-02-26
JP2013199496A (ja) 2013-10-03
CA2668411C (en) 2020-02-25
ES2612755T3 (es) 2017-05-18
CA2668411A1 (en) 2008-05-15
RU2013134324A (ru) 2015-01-27
KR20090085662A (ko) 2009-08-07
US20130344067A1 (en) 2013-12-26
AU2007317926A1 (en) 2008-05-15
CN111518218A (zh) 2020-08-11
IL198522A0 (en) 2011-08-01
US12144860B2 (en) 2024-11-19
MX2009004718A (es) 2009-06-19
US20170354731A1 (en) 2017-12-14
JP2018127471A (ja) 2018-08-16
KR20170012582A (ko) 2017-02-02
EP2087001A2 (en) 2009-08-12
JP2020150955A (ja) 2020-09-24

Similar Documents

Publication Publication Date Title
KR101581961B1 (ko) Ａｌｋ１ 수용체 및 리간드 길항제 및 그의 용도
CA2723449C (en) Methods and compositions based on alk1 antagonists for modulating angiogenesis and pericyte coverage
US9452197B2 (en) Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
KR20140123558A (ko) Alk1 길항제 및 신세포 암종 치료에서의 그의 용도
WO2009139891A2 (en) Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof
AU2018279010B2 (en) ALK1 receptor and ligand antagonists and uses thereof
AU2014200003A1 (en) ALK1 receptor and ligand antagonists and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

A107 Divisional application of patent
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A17-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20191213

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20221225

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20221225

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000